Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Clinical Trials
620
Trial Phases
5 Phases
Drug Approvals
16
Clinical Trials
Distribution across different clinical trial phases (590 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Drug: Best available Treatment (BAT)
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT07124078
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Conditions
- Immune Thrombocytopenia
- Interventions
- Drug: INCA000585
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT07104565
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT07049575
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT07039929
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT07023627
- Locations
- 🇺🇸
Usa Health Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Uams Winthrop P Rockefeller Cancer Institute, Little Rock, Arkansas, United States
🇺🇸University of California, Los Angeles Medical Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 54
- Next
News
Vitiligo Treatment Pipeline Shows Promise with JAK Inhibitors and Novel Immunotherapies in Phase 3 Trials
Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.
Incyte Reports Strong Q2 2025 Results with Jakafi Growth and New Drug Approvals
Incyte reported strong second quarter 2025 financial results with Jakafi net revenues of $764 million, representing 8% year-over-year growth driven by increased demand across all indications.
MacroGenics Secures $70 Million in ZYNYZ Royalty Deal, Extends Cash Runway Through 2027
MacroGenics received a $70 million upfront payment from Sagard Healthcare Partners through a royalty purchase agreement for ZYNYZ, a PD-1 inhibitor approved for anal canal carcinoma and Merkel cell carcinoma.
ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches
The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy.
Essential Thrombocythemia Market Set for Significant Growth as Novel Therapies Enter Pipeline
Essential thrombocythemia affects approximately 167,000 individuals in the US as of 2024, with 75% of cases linked to JAK2 gene mutations and only one approved therapy currently available in Europe.
Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy
Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.
Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025
A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.
Promising Pipeline for Mantle Cell Lymphoma Treatment: 22+ Therapies Under Development by 20+ Companies
DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.
Sun Pharma's Leqselvi Advances Toward Launch After Favorable US Court Ruling
Sun Pharmaceutical Industries has gained significant legal leverage after a US Court of Appeals vacated a preliminary injunction against its alopecia areata treatment Leqselvi, potentially enabling commercialization despite ongoing litigation with Incyte.
U.S. Court Ruling Clears Path for Sun Pharma's Alopecia Drug Leqselvi Launch
The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction against Sun Pharma, allowing the company to proceed with launching Leqselvi (deuruxolitinib) for alopecia areata in the American market.